In The News,
In her conversation with BioWorld, ADVI’s Lindsay Bealor Greenleaf shared her thoughts on the White House’s decision to withdraw the rebate rule, the impacts of the IPI model, and the role of pharmacy benefit managers in the drug supply chain
[el-text]
Written by Mari Serebrov
***excerpt***
“Bealor Greenleaf agreed that the rebate rule would have been the first step to lowering patients’ drug costs, as rebates paid to pharmacy benefit managers (PBMs) and other middlemen costs account for more than 40% of the list price of drugs picked up at the pharmacy. Today’s a big victory for the middlemen, the PBMs specifically,” she added.”
***end excerpt***
[/el-text]